CASI Pharmaceuticals (CASI) Stock Statistics & Valuation Metrics

CASI Pharmaceuticals has a market cap or net worth of $15.28M. The enterprise value is $29.51M.

CASI Pharmaceuticals has 15,492,681 shares outstanding. The number of shares has decreased by -2.65% in one year.

CASI Pharmaceuticals’s return on equity (ROE) is -21.21 and return on invested capital (ROIC) is -108.16%.

The current PE Ratio of CASI Pharmaceuticals is ―. CASI Pharmaceuticals’s PEG ratio is -0.04.

In the last 12 months, CASI Pharmaceuticals had revenue of 28.54M and earned -39.26M in profits. Earnings per share was -2.56.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

CASI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CASI Pharmaceuticals upcoming earnings date is Apr 29, 2026, TBA (Confirmed).

CASI Pharmaceuticals as a current ratio of 1.09, with Debt / Equity ratio of -65.95%

In the past 12 months, CASI Pharmaceuticals has paid 1.19M in taxes.

CASI Pharmaceuticals EV to EBITDA ratio is -1.49, with an EV/FCF ratio of -1.77.

CASI Pharmaceuticals has $4.68M in cash and marketable securities with $18.86M in debt, giving a net cash position of -$14.17M billion.

Gross margin is 35.80%, with operating margin of -138.84%, and net profit margin of -137.57%.

The average price target for CASI Pharmaceuticals is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy